Why the study?
Does ondansetron compared to droperidol or placebo improve cost-effectiveness and prevent postoperative nausea and vomiting in women undergoing outpatient gynecologic surgery?
Population
161 women undergoing elective outpatient gynecologic procedures
Comparison
Ondansetron 4 mg intravenously (IV) vs Droperidol (0.625 mg or 1.25 mg IV) or placebo
Design
RCT, randomized, double-blind
Follow-up
Postoperative and postdischarge
Authors
Loading...
Supports droperidol as cost-effective alternative to ondansetron for PONV prophylaxis; extends cost-effectiveness data in outpatient gynecologic surgery.
Does ondansetron compared to droperidol or placebo improve cost-effectiveness and prevent postoperative nausea and vomiting in women undergoing outpatient gynecologic surgery?
Droperidol 0.625 mg IV provides comparable antiemetic prophylaxis to ondansetron 4 mg IV without increasing side effects, and is more cost-effective for outpatient gynecologic surgery.
Tang et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: